Page last updated: 2024-11-01

nifedipine and Infant, Premature, Diseases

nifedipine has been researched along with Infant, Premature, Diseases in 3 studies

Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.

Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.

Research Excerpts

Excerpt	Relevance	Reference
"The pathophysiology leading to preterm labor is not well understood and often multifactorial; initiating factors include intrauterine infection, inflammation, ischemia, overdistension, and hemorrhage."	2.48	Tocolytic therapy for acute preterm labor. ( Abramovici, A; Cantu, J; Jenkins, SM, 2012)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abramovici, A	1
Cantu, J	1
Jenkins, SM	1
Ozcan, T	1
Turan, C	1
Ekici, E	1
Gökmen, O	1
Doğan, M	1
Kaleli, B	1
Uludağ, H	1
Karayalçin, R	1
Lindley, KJ	1
Dunne, MJ	1
Kane, C	1
Shepherd, RM	1
Squires, PE	1
James, RF	1
Johnson, PR	1
Eckhardt, S	1
Wakeling, E	1
Dattani, M	1
Milla, PJ	1
Aynsley-Green, A	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis[NCT01869361]	Early Phase 1	0 participants (Actual)	Interventional	2020-08-01	Withdrawn (stopped due to Due to much lower than expected numbers of eligible patients and lack of PI time, the study was not started.)
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]		11,976 participants (Actual)	Interventional	2016-03-23	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	189
Placebo Arm	230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	1078
Placebo Arm	1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	78
Placebo Arm	101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	303
Placebo Arm	353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	134
Placebo Arm	152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	141
Placebo Arm	166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	42
Placebo Arm	30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

Intervention	Participants (Count of Participants)
Intervention Arm	352
Placebo Arm	325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	264
Placebo Arm	309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

Intervention	Participants (Count of Participants)
Intervention Arm	668
Placebo Arm	754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	1506
Placebo Arm	1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	214
Placebo Arm	246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	26
Placebo Arm	25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	54
Placebo Arm	43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	9
Placebo Arm	12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	23
Placebo Arm	30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

Intervention	Participants (Count of Participants)
Intervention Arm	290
Placebo Arm	333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Intervention	Participants (Count of Participants)
Intervention Arm	8
Placebo Arm	21

Reviews

1 review available for nifedipine and Infant, Premature, Diseases

Article	Year
Tocolytic therapy for acute preterm labor. Obstetrics and gynecology clinics of North America, 2012, Volume: 39, Issue:1 Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci	2012
Tocolytic therapy for acute preterm labor. Obstetrics and gynecology clinics of North America, 2012, Volume: 39, Issue:1 Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci	2012
Tocolytic therapy for acute preterm labor. Obstetrics and gynecology clinics of North America, 2012, Volume: 39, Issue:1 Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci	2012
Tocolytic therapy for acute preterm labor. Obstetrics and gynecology clinics of North America, 2012, Volume: 39, Issue:1 Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci	2012

Other Studies

2 other studies available for nifedipine and Infant, Premature, Diseases

Article	Year
Ritodrine tocolysis and neonatal intraventricular-periventricular hemorrhage. Gynecologic and obstetric investigation, 1995, Volume: 39, Issue:1 Topics: Cerebral Hemorrhage; Cerebral Ventricles; Female; Humans; Infant, Newborn; Infant, Premature, Diseas	1995
Ionic control of beta cell function in nesidioblastosis. A possible therapeutic role for calcium channel blockade. Archives of disease in childhood, 1996, Volume: 74, Issue:5 Topics: Blood Glucose; Calcium Channel Blockers; Calcium Channels; Electrophysiology; Female; Humans; Infant	1996